Please login to the form below

Not currently logged in
Email:
Password:

Defitelio

This page shows the latest Defitelio news and features for those working in and with pharma, biotech and healthcare.

Jazz Pharma bags FDA approval for rare disease drug

Jazz Pharma bags FDA approval for rare disease drug

Jazz acquired Defitelio as part of its $1bn purchase of Italy's Gentium in 2013. ... The company has the opportunity to promote both Erwinaze and Defitelio via its haematology/oncology salesforce, it noted.

Latest news

  • SMC: Celgene's Abraxane 'too expensive' for Scotland SMC: Celgene's Abraxane 'too expensive' for Scotland

    SMC: Celgene's Abraxane 'too expensive' for Scotland. But medicines watchdog backs Sovaldi, Invokana, Defitelio, Relvar Ellipta. ... Drugs that received positive opinions included Janssen's Invokana (canagliflozin) for type 2 diabetes, Jazz

  • Jazz offers $1bn for Italy's Gentium Jazz offers $1bn for Italy's Gentium

    Jazz offers $1bn for Italy's Gentium. Will gain access to recently-approved liver drug Defitelio. ... 10m. Gentium also has a small business unit selling active pharmaceutical ingredients (APIs) which contributed the bulk of the non-Defitelio turnover.

  • Gentium expects EMA rejection for defibrotide Gentium expects EMA rejection for defibrotide

    Negative feedback for drug’s use in liver condition associated with stem cell transplantation

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics